Allurion Technologies has launched its Virtual Care Suite (VCS) in the United States. It provides a comprehensive weight loss management platform for providers offering GLP-1 medications, bariatric surgery, and other weight loss devices.
The VCS combines remote patient monitoring, telehealth, and care team collaboration in one digital platform, optimizing patient outcomes and satisfaction. Its AI-powered functionality includes Coach Iris, a 24/7 weight loss coach that personalizes behavior change programs.
Studies have shown that VCS usage leads to enhanced patient results, with 11% additional weight loss, 16% more goal achievement, and a 17% increase in Net Promoter Score (NPS). The platform has been successful in over 50 countries and is now available to US providers for the first time at the Obesity Medicine Conference in Denver on April 25.
Allurion believes the VCS can be integral to weight loss practices, especially with the growing use of GLP-1 medications. The launch includes a new version of Allurion Insights, a provider dashboard for VCS navigation.
The VCS is also available to providers separately from Allurion’s Gastric Balloon Program. It allows customization and management of weight loss therapy for patients regardless of treatment plan. This comprehensive platform empowers providers with digital solutions to enhance clinical outcomes and improve patient experiences in the fight against obesity.
Source link: http://www.businesswire.com/news/home/20240404646972/en/Allurion-Expands-Virtual-Care-Suite-to-the-United-States
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
